With the early health technology assessment based on manufacturers' dossiers, the Pharmaceutical Market Restructuring Act introduced a new instrument of drug regulation in Germany. In order to determine reimbursability or pricing of drugs, this approach is already as common abroad as the
evidence-based full assessment of benefit or cost effectiveness. This paper examines the concepts and experiences of drug evaluation in other countries and attempts to classify the current situation in Germany in an international context.